Gastrointestinal side effects of incretin-based obesity management medications: insights from healthcare professionals and patients’ experiences
Authors' conclusion
Newly identified characteristics of GI side effects have emerged, enabling a more comprehensive understanding of the phenomenon. Moreover, HCPs proposed detailed strategies for preventing and managing GI side effects. The insights gained could be beneficial for both HCPs and patients aiming to improve the quality of care and medication adherence.
Study context
- Population
- Healthcare professionals (HCPs) and patients treated with incretin-based obesity management medications (OMMs)
- Participants
- 7 vs 8
- Comparison
- HCPs vs Patients
- HCPsn = 7
- Patientsn = 8
- Outcome
- Perceptions and experiences of GI side effects of incretin-based OMMs
Methodological detailsfocus groups, semi-structured interviews, qualitative content analysis
- Focus groups
- Semi-structured interviews
- Qualitative content analysis
Main finding
As reported in the abstract
- Theme 1: characteristics of gastrointestinal (GI) side effects — types of common GI side effects; timing of occurrence; challenges in diagnosis; impact on quality of life and treatment continuity
- Theme 2: prevention and management strategies — preliminary education; tailored dose escalation; dietary and lifestyle modifications for specific GI symptoms; medical therapy to alleviate symptoms; multidisciplinary follow-up
Original publication
Gastrointestinal side effects of incretin-based obesity management medications: insights from healthcare professionals and patients’ experiences. Int J Obes (Lond). Published 28 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →